High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.

Wilke RA
Pharmacogenomics J. 2011 11 (3): 162-73

PMID: 21151197 · PMCID: PMC3309611 · DOI:10.1038/tpj.2010.86

Over the past decade, large multicenter trials have unequivocally demonstrated that decreasing low-density lipoprotein (LDL) cholesterol can reduce both primary and secondary cardiovascular events in patients at risk. However, even in the context of maximal LDL lowering, there remains considerable residual cardiovascular risk. Some of this risk can be attributed to variability in high-density lipoprotein (HDL) cholesterol. As such, there is tremendous interest in defining determinants of HDL homeostasis. Risk prediction models are being constructed based upon (1) clinical contributors, (2) known molecular determinants and (3) the genetic architecture underlying HDL cholesterol levels. To date, however, no single resource has combined these factors within the context of a practice-based data set. Recently, a number of academic medical centers have begun constructing DNA biobanks linked to secure encrypted versions of their respective electronic medical record. As these biobanks combine resources, the clinical community is in a position to characterize lipid-related treatment outcome on an unprecedented scale.

MeSH Terms (18)

Apolipoprotein A-I Atorvastatin Cholesterol, HDL Cholesterol, LDL Databases, Nucleic Acid Dose-Response Relationship, Drug Dyslipidemias Electronic Health Records Genetic Association Studies Genetic Markers Heptanoic Acids Humans Obesity Pravastatin Pyrroles Risk Assessment Simvastatin Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: